Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Hypomethylation of intron 1 of the α‐synuclein (<i>SNCA</i>) gene has been extensively reported in the blood of patients with α‐synucleinopathies. Idiopathic rapid eye movement sleep behavior disorder represents a prodromal stage of α‐synucleinopathies. Methylation of α‐synuclein intron 1 in idiopathic rapid eye movement sleep behavior disorder patients is largely unexplored. The objective of the current study was to assess blood α‐synuclein intron 1 methylation in patients and to explore it as a potential biomarker to predict phenoconversion and monitor disease progression. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Seventy‐eight polysomnography‐confirmed patients and 74 healthy controls were enrolled. After an average of 3.75 years of follow up, 16 patients converted to neurodegenerative diseases (converters), whereas 59 did not (nonconverters). Blood DNA was obtained at baseline from all participants, as well as at the follow‐up visit for 27 patients. DNA methylation levels were determined using bisulfite pyrosequencing methods and were compared between patients and healthy controls, converters and nonconverters, and baseline and follow‐up visits.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Hypomethylation at cytosine‐phosphate‐guanine 10, 11, 12, 13, and 17 was found in patients compared with healthy controls. Hypomethylation at cytosine‐phosphate‐guanine 17 was associated with an increased risk of clinical phenoconversion, which was further enhanced with the presence of subtle motor abnormalities. In addition, it appeared that later reduction in methylation levels at cytosine‐phosphate‐guanine 14, 15, and 16 was associated with disease progression.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Peripheral blood α‐synuclein intron 1 was hypomethylated in idiopathic rapid eye movement sleep behavior disorder patients. α‐Synuclein methylation levels may be useful biomarkers to screen patients, predict phenoconversion, and monitor disease progression. © 2020 International Parkinson and Movement Disorder Society</p></section>

SNCA Hypomethylation in Rapid Eye Movement Sleep Behavior Disorder Is a Potential Biomarker for Parkinson's Disease.

Hypomethylation of SNCA in Idiopathic REM Sleep Behavior Disorder Associated With Phenoconversion

Different Patterns of Exosomal Α‐synuclein Between Parkinson's Disease and Probable Rapid Eye Movement Sleep Behavior Disorder

Abnormal Baseline Brain Activity in Parkinson's Disease with and Without REM Sleep Behavior Disorder: A Resting‐state Functional MRI Study

Alterations of Brain Structural Network in Parkinson’s Disease with and Without Rapid Eye Movement Sleep Behavior Disorder

Microstructural Alterations of the Hypothalamus in Parkinson's Disease and Probable REM Sleep Behavior Disorder

Altered Nigrostriatal and Nigrocortical Functional Connectivity in Rapid Eye Movement Sleep Behavior Disorder

Impaired Ocular Tracking and Cortical Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson’s disease and normal control

Wider and Faster Degeneration of White Matter in Parkinson’s Disease with Possible REM Sleep Behaviour Disorder

The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease

Functional Neuroimaging in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Methylation of Α-Synuclein and Leucine-Rich Repeat Kinase 2 in Leukocyte DNA of Parkinson's Disease Patients

Increased Free-Water in the Substantia Nigra in Idiopathic REM Sleep Behaviour Disorder

Rapid Eye Movement Sleep Behavior Disorder As a Predicting Phenomenon of Α-Synucleinopathies( Report of 1 Case)

Increased mean diffusivity of the caudal motor SNc identifies patients with REM sleep behaviour disorder and Parkinson’s disease

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy

DNA methylation age acceleration as a potential biomarker for early onset of REM sleep behavior disorder

Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease

Alloreactive T cells that do not require TCR and CD8 coengagement are present in naive mice and contribute to graft rejection.